Programs

Idiopathic Pulmonary Fibrosis

Audax is developing inhaled EPAC1 agonists for IPF. Inhaled EPAC1 agonists can be differentiated from existing therapies because they promote activation of pre-existing anti-inflammatory/antifibrotic mechanisms. By directly inhibiting the excessive inflammatory and fibrotic response within the lung, EPAC1 agonists are predicted to normalise the rate of loss in lung function seen in IPF patients.

This project is at lead identification stage

Pulmonary Arterial Hypertension

The ability of EPAC1 partial agonists to inhibit NLRP3 inflammasome, TGFβ signalling, JAK/STAT activation and disrupt pro-inflammatory communication between macrophages and VECs highlights the importance for EPAC1 in coordinating the progression of vascular inflammation and identifies a new, druggable route to treat PAH.

This project is at hit-to-lead stage.